Which patients with locally advanced cervical cancer would you consider as candidates for moderately hypofractionated pelvic chemoradiation before brachytherapy?
Per Gandhi et al., PMID 41319720, patients received H-EBRT of 40 Gy in 16 fractions over 3.1 weeks with a sequential boost of 10 Gy in 4 fractions to pelvic lymph nodes, and concurrent weekly cisplatin 40 mg/m2. This was followed by brachytherapy of 28 Gy in 4 fractions delivered over 2 to 4 applications.
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on
At present, would not offer outside clinical trials, as data are limited, with some suggesting a higher risk of acute morbidity also. Doses of EBRT in these studies are also not similar, varying from 37.5 in 15, 40 in 16, 44 in 20, and 43.3 in 17.
Join for free or sign in to see the full answer